Christopher Thomas Giordano
CEO at Tenax Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 2 years
- Director since
- 2024
2 years of board service in total across 1 board, counting each seat separately. Longest: Tenax Therapeutics Inc., 2 years.
Tenax Therapeutics Inc.
Director · CEO
Chief executive roles
Tenax Therapeutics Inc.
· CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 13, 2026 | Tenax Therapeutics Inc. | Option exercise | +219 | $3.55 | $777 |
| Jul 13, 2026 | Tenax Therapeutics Inc. | Option exercise | +8,500 | $5.94 | $50,490 |
| Nov 20, 2025 | Tenax Therapeutics Inc. | Open-market purchase | +538 | $7.59 | $4,083 |
| Nov 19, 2025 | Tenax Therapeutics Inc. | Open-market purchase | +455 | $7.51 | $3,417 |
| Nov 18, 2025 | Tenax Therapeutics Inc. | Open-market purchase | +1,612 | $7.75 | $12,493 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.